GT Biopharma Inc expected to post a loss of 17  cents a share - Earnings Preview

GT Biopharma

09/08/2022 19:34

* GT Biopharma Inc  GTBP.OQ   GTBP.O  is expected to show no
change in quarterly revenue when it reports  results on August
11 (estimated). 
    * ​Refinitiv's mean analyst estimate for GT Biopharma Inc is
for a
loss of 17 cents per share. For the same quarter last year, the
company reported a loss of 13 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for GT
Biopharma Inc
is $17​, above​ its last closing price of $2.95. ​​​

This summary was machine generated August 9 at 18:32 GMT.  All
figures in US dollars  unless otherwise stated